Imricor Historical Income Statement

IMR Stock

1.07 0.04 3.60%

Historical analysis of Imricor Medical income statement accounts such as Depreciation And Amortization of 525.5 K or Interest Expense of 45.5 K can show how well Imricor Medical Systems performed in making a profits. Evaluating Imricor Medical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Imricor Medical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Imricor Medical Systems latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imricor Medical Systems is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imricor Medical Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Imricor Income Statement Analysis

Imricor Medical Systems Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Imricor Medical shareholders. The income statement also shows Imricor investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Imricor Medical Income Statement Chart

Net Interest Income is likely to gain to about 15.8 K in 2024, whereas Interest Income is likely to drop slightly above 59.9 K in 2024.

Selling General Administrative Total Revenue Research Development Extraordinary Items

Total Revenue

Total revenue comprises all receipts Imricor Medical Systems generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Imricor Medical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Imricor Medical Systems current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imricor Medical Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Interest Income is likely to gain to about 15.8 K in 2024, whereas Interest Income is likely to drop slightly above 59.9 K in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	918.1K	1.0M	707.5K	525.5K
Interest Income	16.7K	108.0K	63.0K	59.9K

Depreciation And Amortization Interest Income

Imricor Medical income statement Correlations

	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Selling And Marketing Expenses	Reconciled Depreciation
Interest Income		-0.16	0.97	-0.05	0.47	0.3	0.07	-0.02	-0.17	0.02	-0.2	0.01	-0.15	0.22	-0.04	-0.07	-0.07	0.57	-0.24	-0.23	-0.23
Depreciation And Amortization	-0.16		-0.13	0.96	-0.12	-0.96	0.95	-0.91	-0.82	-0.87	0.93	-0.86	0.99	0.44	-0.86	-0.35	-0.86	0.29	0.92	0.96	0.96
Interest Expense	0.97	-0.13		0.01	0.61	0.29	0.09	-0.01	-0.16	0.04	-0.15	0.03	-0.1	0.31	-0.02	-0.01	-0.06	0.55	-0.19	-0.19	-0.19
Selling General Administrative	-0.05	0.96	0.01		-0.06	-0.92	0.97	-0.95	-0.89	-0.92	0.94	-0.91	0.96	0.37	-0.92	-0.48	-0.92	0.37	0.95	0.96	0.96
Total Revenue	0.47	-0.12	0.61	-0.06		0.35	-0.11	0.18	0.23	0.22	-0.06	0.22	-0.04	0.16	0.19	0.18	0.2	-0.14	-0.17	-0.15	-0.15
Gross Profit	0.3	-0.96	0.29	-0.92	0.35		-0.92	0.93	0.83	0.9	-0.91	0.9	-0.95	-0.31	0.88	0.43	0.88	-0.28	-0.93	-0.96	-0.95
Other Operating Expenses	0.07	0.95	0.09	0.97	-0.11	-0.92		-0.97	-0.93	-0.93	0.91	-0.92	0.95	0.44	-0.93	-0.46	-0.94	0.5	0.89	0.93	0.92
Operating Income	-0.02	-0.91	-0.01	-0.95	0.18	0.93	-0.97		0.96	0.98	-0.9	0.98	-0.92	-0.25	0.98	0.62	0.99	-0.39	-0.94	-0.95	-0.94
Net Income From Continuing Ops	-0.17	-0.82	-0.16	-0.89	0.23	0.83	-0.93	0.96		0.95	-0.76	0.95	-0.81	-0.19	0.97	0.69	0.98	-0.53	-0.87	-0.85	-0.86
Ebit	0.02	-0.87	0.04	-0.92	0.22	0.9	-0.93	0.98	0.95		-0.87	1.0	-0.88	-0.09	1.0	0.73	0.99	-0.3	-0.94	-0.94	-0.94
Research Development	-0.2	0.93	-0.15	0.94	-0.06	-0.91	0.91	-0.9	-0.76	-0.87		-0.87	0.96	0.32	-0.86	-0.41	-0.85	0.16	0.9	0.96	0.94
Ebitda	0.01	-0.86	0.03	-0.91	0.22	0.9	-0.92	0.98	0.95	1.0	-0.87		-0.87	-0.07	1.0	0.74	0.99	-0.3	-0.93	-0.93	-0.93
Cost Of Revenue	-0.15	0.99	-0.1	0.96	-0.04	-0.95	0.95	-0.92	-0.81	-0.88	0.96	-0.87		0.42	-0.87	-0.36	-0.86	0.27	0.92	0.97	0.95
Total Operating Expenses	0.22	0.44	0.31	0.37	0.16	-0.31	0.44	-0.25	-0.19	-0.09	0.32	-0.07	0.42		-0.1	0.56	-0.14	0.64	0.14	0.22	0.19
Income Before Tax	-0.04	-0.86	-0.02	-0.92	0.19	0.88	-0.93	0.98	0.97	1.0	-0.86	1.0	-0.87	-0.1		0.74	1.0	-0.34	-0.93	-0.93	-0.93
Total Other Income Expense Net	-0.07	-0.35	-0.01	-0.48	0.18	0.43	-0.46	0.62	0.69	0.73	-0.41	0.74	-0.36	0.56	0.74		0.72	0.02	-0.62	-0.54	-0.57
Net Income	-0.07	-0.86	-0.06	-0.92	0.2	0.88	-0.94	0.99	0.98	0.99	-0.85	0.99	-0.86	-0.14	1.0	0.72		-0.4	-0.92	-0.91	-0.92
Income Tax Expense	0.57	0.29	0.55	0.37	-0.14	-0.28	0.5	-0.39	-0.53	-0.3	0.16	-0.3	0.27	0.64	-0.34	0.02	-0.4		0.16	0.17	0.16
Net Interest Income	-0.24	0.92	-0.19	0.95	-0.17	-0.93	0.89	-0.94	-0.87	-0.94	0.9	-0.93	0.92	0.14	-0.93	-0.62	-0.92	0.16		0.98	0.99
Selling And Marketing Expenses	-0.23	0.96	-0.19	0.96	-0.15	-0.96	0.93	-0.95	-0.85	-0.94	0.96	-0.93	0.97	0.22	-0.93	-0.54	-0.91	0.17	0.98		1.0
Reconciled Depreciation	-0.23	0.96	-0.19	0.96	-0.15	-0.95	0.92	-0.94	-0.86	-0.94	0.94	-0.93	0.95	0.19	-0.93	-0.57	-0.92	0.16	0.99	1.0

Click cells to compare fundamentals

Imricor Medical Account Relationship Matchups

Imricor Medical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Income	800.7K	38.0K	16.7K	108.0K	63.0K	59.9K
Depreciation And Amortization	257.3K	528.1K	918.1K	1.0M	707.5K	525.5K
Interest Expense	1.0M	300.6K	108.8K	177.9K	47.9K	45.5K
Selling General Administrative	2.6M	4.3M	5.8M	5.0M	5.1M	3.9M
Total Revenue	639.7K	702.2K	696.3K	816.0K	615.6K	608.2K
Gross Profit	262.3K	(397.7K)	(1.9M)	(1.5M)	(1.1M)	(1.1M)
Other Operating Expenses	13.4M	13.2M	21.7M	18.8M	17.5M	14.5M
Operating Income	(12.0M)	(11.6M)	(19.6M)	(17.2M)	(17.6M)	(18.5M)
Net Income From Continuing Ops	(19.0M)	(16.2M)	(19.7M)	(17.4M)	(22.6M)	(21.5M)
Ebit	(12.0M)	(11.6M)	(19.9M)	(17.5M)	(22.6M)	(21.4M)
Research Development	3.6M	5.5M	9.7M	7.9M	7.9M	6.6M
Ebitda	(11.7M)	(11.1M)	(18.9M)	(16.5M)	(21.9M)	(20.8M)
Total Operating Expenses	13.0M	12.1M	19.1M	16.5M	(1.1M)	(1.1M)
Income Before Tax	(13.3M)	(12.4M)	(19.7M)	(17.4M)	(22.6M)	(21.5M)
Total Other Income Expense Net	(1.3M)	(828.7K)	(108.8K)	(177.9K)	(5.1M)	(4.8M)
Net Income Applicable To Common Shares	(13.3M)	(12.4M)	(19.7M)	(17.4M)	(15.6M)	(16.4M)
Net Income	(14.8M)	(13.1M)	(20.6M)	(17.5M)	(22.6M)	(21.5M)
Income Tax Expense	4.0	1.5M	630.3K	823.6K	177.9K	(3.8)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Imricor Stock Analysis

When running Imricor Medical's price analysis, check to measure Imricor Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imricor Medical is operating at the current time. Most of Imricor Medical's value examination focuses on studying past and present price action to predict the probability of Imricor Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imricor Medical's price. Additionally, you may evaluate how the addition of Imricor Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Imricor Historical Income Statement

About Imricor Income Statement Analysis

Imricor Medical Income Statement Chart

Total Revenue

Imricor Medical income statement Correlations

Imricor Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Imricor Medical income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Imricor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Interest Income
Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Ebitda	Cost Of Revenue
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Extraordinary Items	Net Interest Income
Selling And Marketing Expenses	Reconciled Depreciation

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda
Net Income	+ 1.0	Income Before Tax
Reconciled Depreciation	+ 1.0	Selling And Marketing Expenses
Cost Of Revenue	+ 0.99	Depreciation And Amortization

Operating Income	- 0.97	Other Operating Expenses
Selling And Marketing Expenses	- 0.96	Gross Profit
Gross Profit	- 0.96	Depreciation And Amortization
Selling And Marketing Expenses	- 0.95	Operating Income
Reconciled Depreciation	- 0.95	Gross Profit
Cost Of Revenue	- 0.95	Gross Profit